APO Research
Talk to an analyst

APO RESEARCH · REPORT

NASH Drug Pipeline

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global NASH Drug Pipeline Industry Growth and Trends Forecast to 2032

2 January 2026123 pages

Choose your research edition.

Industry ResearchNASH Drug Pipeline Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal NASH Drug Pipeline Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal NASH Drug Pipeline Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NASH Drug Pipeline Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal NASH Drug Pipeline Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global NASH Drug Pipeline market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for NASH Drug Pipeline is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for NASH Drug Pipeline is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NASH Drug Pipeline is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NASH Drug Pipeline include 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Allergan and ChemomAb Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global NASH Drug Pipeline market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The NASH Drug Pipeline market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global NASH Drug Pipeline market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to NASH Drug Pipeline.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global NASH Drug Pipeline market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

NASH Drug Pipeline Market by Company

89bio Inc

ABIONYX Pharma SA

Abivax SA

Abliva AB

Acquist Therapeutics

AdAlta Ltd

Afimmune Biopharma Ltd

Allergan

ChemomAb Ltd

Dicerna Pharmaceuticals Inc

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

EncuraGen Inc

Engitix Ltd

Galectin

Genfit

Gilead

Heprotech Inc

Hinova Pharmaceuticals Inc

HK inno.N Corp

HotSpot Therapeutics Inc

Immuron

Intercept

Madrigal

Zhejiang Doer Biologics Corp

NASH Drug Pipeline Segment by Type

By Molecule Types

By Route of Administration:

By Mechanism of Action

NASH Drug Pipeline Segment by Application

Clinical

Academic Research

NASH Drug Pipeline Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NASH Drug Pipeline market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NASH Drug Pipeline and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NASH Drug Pipeline.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of NASH Drug Pipeline manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of NASH Drug Pipeline in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of By Molecule Types Table 2. Major Company of By Route of Administration: Table 3. Major Company of By Mechanism of Action Table 4. Global NASH Drug Pipeline Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 6. Global NASH Drug Pipeline Sales Market Share in Volume by Type (2021-2026) Table 7. Global NASH Drug Pipeline Sales by Type (2021-2026) & (US$ Million) Table 8. Global NASH Drug Pipeline Sales Market Share in Value by Type (2021-2026) Table 9. Global NASH Drug Pipeline Price by Type (2021-2026) & (US$/Unit) Table 10. Global NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 11. Global NASH Drug Pipeline Sales Market Share in Volume by Type (2027-2032) Table 12. Global NASH Drug Pipeline Sales by Type (2027-2032) & (US$ Million) Table 13. Global NASH Drug Pipeline Sales Market Share in Value by Type (2027-2032) Table 14. Global NASH Drug Pipeline Price by Type (2027-2032) & (US$/Unit) Table 15. North America NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 16. North America NASH Drug Pipeline Sales by Type (2021-2026) & (US$ Million) Table 17. Europe NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 18. Europe NASH Drug Pipeline Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific NASH Drug Pipeline Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 22. Latin America NASH Drug Pipeline Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa NASH Drug Pipeline Sales by Type (2021-2026) & (US$ Million) Table 25. NASH Drug Pipeline Industry Trends Table 26. NASH Drug Pipeline Industry Drivers Table 27. NASH Drug Pipeline Industry Opportunities and Challenges Table 28. NASH Drug Pipeline Industry Restraints Table 29. Global NASH Drug Pipeline Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global NASH Drug Pipeline Revenue Market Share by Company (2021-2026) Table 31. Global NASH Drug Pipeline Sales by Company (2021-2026) & (K Units) Table 32. Global NASH Drug Pipeline Sales Share by Company (2021-2026) Table 33. Global NASH Drug Pipeline Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global NASH Drug Pipeline Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global NASH Drug Pipeline Major Company Production Sites and Headquarters Table 36. Global NASH Drug Pipeline Company, Product Type & Application Table 37. Global NASH Drug Pipeline Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global NASH Drug Pipeline by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global NASH Drug Pipeline Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global NASH Drug Pipeline Sales by Region (2021-2026) & (K Units) Table 42. Global NASH Drug Pipeline Sales Market Share in Volume by Region (2021-2026) Table 43. Global NASH Drug Pipeline Sales by Region (2021-2026) & (US$ Million) Table 44. Global NASH Drug Pipeline Sales Market Share in Value by Region (2021-2026) Table 45. Global NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global NASH Drug Pipeline Sales by Region (2027-2032) & (K Units) Table 47. Global NASH Drug Pipeline Sales Market Share in Volume by Region (2027-2032) Table 48. Global NASH Drug Pipeline Sales by Region (2027-2032) & (US$ Million) Table 49. Global NASH Drug Pipeline Sales Market Share in Value by Region (2027-2032) Table 50. Global NASH Drug Pipeline Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global NASH Drug Pipeline Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 53. Global NASH Drug Pipeline Sales Market Share in Volume by Application (2021-2026) Table 54. Global NASH Drug Pipeline Sales by Application (2021-2026) & (US$ Million) Table 55. Global NASH Drug Pipeline Sales Market Share in Value by Application (2021-2026) Table 56. Global NASH Drug Pipeline Price by Application (2021-2026) & (US$/Unit) Table 57. Global NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 58. Global NASH Drug Pipeline Sales Market Share in Volume by Application (2027-2032) Table 59. Global NASH Drug Pipeline Sales by Application (2027-2032) & (US$ Million) Table 60. Global NASH Drug Pipeline Sales Market Share in Value by Application (2027-2032) Table 61. Global NASH Drug Pipeline Price by Application (2027-2032) & (US$/Unit) Table 62. North America NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 63. North America NASH Drug Pipeline Sales by Application (2021-2026) & (US$ Million) Table 64. Europe NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 65. Europe NASH Drug Pipeline Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific NASH Drug Pipeline Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 69. Latin America NASH Drug Pipeline Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa NASH Drug Pipeline Sales by Application (2021-2026) & (US$ Million) Table 72. 89bio Inc Company Information Table 73. 89bio Inc Business Overview Table 74. 89bio Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. 89bio Inc NASH Drug Pipeline Product Portfolio Table 76. 89bio Inc Recent Development Table 77. ABIONYX Pharma SA Company Information Table 78. ABIONYX Pharma SA Business Overview Table 79. ABIONYX Pharma SA NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio Table 81. ABIONYX Pharma SA Recent Development Table 82. Abivax SA Company Information Table 83. Abivax SA Business Overview Table 84. Abivax SA NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Abivax SA NASH Drug Pipeline Product Portfolio Table 86. Abivax SA Recent Development Table 87. Abliva AB Company Information Table 88. Abliva AB Business Overview Table 89. Abliva AB NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Abliva AB NASH Drug Pipeline Product Portfolio Table 91. Abliva AB Recent Development Table 92. Acquist Therapeutics Company Information Table 93. Acquist Therapeutics Business Overview Table 94. Acquist Therapeutics NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Acquist Therapeutics NASH Drug Pipeline Product Portfolio Table 96. Acquist Therapeutics Recent Development Table 97. AdAlta Ltd Company Information Table 98. AdAlta Ltd Business Overview Table 99. AdAlta Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AdAlta Ltd NASH Drug Pipeline Product Portfolio Table 101. AdAlta Ltd Recent Development Table 102. Afimmune Biopharma Ltd Company Information Table 103. Afimmune Biopharma Ltd Business Overview Table 104. Afimmune Biopharma Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio Table 106. Afimmune Biopharma Ltd Recent Development Table 107. Allergan Company Information Table 108. Allergan Business Overview Table 109. Allergan NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Allergan NASH Drug Pipeline Product Portfolio Table 111. Allergan Recent Development Table 112. ChemomAb Ltd Company Information Table 113. ChemomAb Ltd Business Overview Table 114. ChemomAb Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. ChemomAb Ltd NASH Drug Pipeline Product Portfolio Table 116. ChemomAb Ltd Recent Development Table 117. Dicerna Pharmaceuticals Inc Company Information Table 118. Dicerna Pharmaceuticals Inc Business Overview Table 119. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 121. Dicerna Pharmaceuticals Inc Recent Development Table 122. DURECT Corp Company Information Table 123. DURECT Corp Business Overview Table 124. DURECT Corp NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. DURECT Corp NASH Drug Pipeline Product Portfolio Table 126. DURECT Corp Recent Development Table 127. Eli Lilly and Co Company Information Table 128. Eli Lilly and Co Business Overview Table 129. Eli Lilly and Co NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Eli Lilly and Co NASH Drug Pipeline Product Portfolio Table 131. Eli Lilly and Co Recent Development Table 132. Enanta Pharmaceuticals Inc Company Information Table 133. Enanta Pharmaceuticals Inc Business Overview Table 134. Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 136. Enanta Pharmaceuticals Inc Recent Development Table 137. EncuraGen Inc Company Information Table 138. EncuraGen Inc Business Overview Table 139. EncuraGen Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. EncuraGen Inc NASH Drug Pipeline Product Portfolio Table 141. EncuraGen Inc Recent Development Table 142. Engitix Ltd Company Information Table 143. Engitix Ltd Business Overview Table 144. Engitix Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Engitix Ltd NASH Drug Pipeline Product Portfolio Table 146. Engitix Ltd Recent Development Table 147. Galectin Company Information Table 148. Galectin Business Overview Table 149. Galectin NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Galectin NASH Drug Pipeline Product Portfolio Table 151. Galectin Recent Development Table 152. Genfit Company Information Table 153. Genfit Business Overview Table 154. Genfit NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Genfit NASH Drug Pipeline Product Portfolio Table 156. Genfit Recent Development Table 157. Gilead Company Information Table 158. Gilead Business Overview Table 159. Gilead NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Gilead NASH Drug Pipeline Product Portfolio Table 161. Gilead Recent Development Table 162. Heprotech Inc Company Information Table 163. Heprotech Inc Business Overview Table 164. Heprotech Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 165. Heprotech Inc NASH Drug Pipeline Product Portfolio Table 166. Heprotech Inc Recent Development Table 167. Hinova Pharmaceuticals Inc Company Information Table 168. Hinova Pharmaceuticals Inc Business Overview Table 169. Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 170. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 171. Hinova Pharmaceuticals Inc Recent Development Table 172. HK inno.N Corp Company Information Table 173. HK inno.N Corp Business Overview Table 174. HK inno.N Corp NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 175. HK inno.N Corp NASH Drug Pipeline Product Portfolio Table 176. HK inno.N Corp Recent Development Table 177. HotSpot Therapeutics Inc Company Information Table 178. HotSpot Therapeutics Inc Business Overview Table 179. HotSpot Therapeutics Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 180. HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio Table 181. HotSpot Therapeutics Inc Recent Development Table 182. Immuron Company Information Table 183. Immuron Business Overview Table 184. Immuron NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 185. Immuron NASH Drug Pipeline Product Portfolio Table 186. Immuron Recent Development Table 187. Intercept Company Information Table 188. Intercept Business Overview Table 189. Intercept NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 190. Intercept NASH Drug Pipeline Product Portfolio Table 191. Intercept Recent Development Table 192. Madrigal Company Information Table 193. Madrigal Business Overview Table 194. Madrigal NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 195. Madrigal NASH Drug Pipeline Product Portfolio Table 196. Madrigal Recent Development Table 197. Zhejiang Doer Biologics Corp Company Information Table 198. Zhejiang Doer Biologics Corp Business Overview Table 199. Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 200. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio Table 201. Zhejiang Doer Biologics Corp Recent Development Table 202. North America NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 203. North America NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 204. North America NASH Drug Pipeline Sales Market Share by Country (2021-2026) Table 205. North America NASH Drug Pipeline Sales Forecast by Country (2027-2032) & (K Units) Table 206. North America NASH Drug Pipeline Sales Market Share Forecast by Country (2027-2032) Table 207. North America NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 208. North America NASH Drug Pipeline Market Size by Country (2021-2026) & (US$ Million) Table 209. North America NASH Drug Pipeline Market Share by Country (2021-2026) Table 210. North America NASH Drug Pipeline Market Size Forecast by Country (2027-2032) & (US$ Million) Table 211. North America NASH Drug Pipeline Market Share Forecast by Country (2027-2032) Table 212. Europe NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 213. Europe NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 214. Europe NASH Drug Pipeline Sales Market Share by Country (2021-2026) Table 215. Europe NASH Drug Pipeline Sales Forecast by Country (2027-2032) & (K Units) Table 216. Europe NASH Drug Pipeline Sales Market Share Forecast by Country (2027-2032) Table 217. Europe NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 218. Europe NASH Drug Pipeline Market Size by Country (2021-2026) & (US$ Million) Table 219. Europe NASH Drug Pipeline Market Share by Country (2021-2026) Table 220. Europe NASH Drug Pipeline Market Size Forecast by Country (2027-2032) & (US$ Million) Table 221. Europe NASH Drug Pipeline Market Share Forecast by Country (2027-2032) Table 222. Asia-Pacific NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 223. Asia-Pacific NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 224. Asia-Pacific NASH Drug Pipeline Sales Market Share by Country (2021-2026) Table 225. Asia-Pacific NASH Drug Pipeline Sales Forecast by Country (2027-2032) & (K Units) Table 226. Asia-Pacific NASH Drug Pipeline Sales Market Share Forecast by Country (2027-2032) Table 227. Asia-Pacific NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 228. Asia-Pacific NASH Drug Pipeline Market Size by Country (2021-2026) & (US$ Million) Table 229. Asia-Pacific NASH Drug Pipeline Market Share by Country (2021-2026) Table 230. Asia-Pacific NASH Drug Pipeline Market Size Forecast by Country (2027-2032) & (US$ Million) Table 231. Asia-Pacific NASH Drug Pipeline Market Share Forecast by Country (2027-2032) Table 232. Latin America NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 233. Latin America NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 234. Latin America NASH Drug Pipeline Sales Market Share by Country (2021-2026) Table 235. Latin America NASH Drug Pipeline Sales Forecast by Country (2027-2032) & (K Units) Table 236. Latin America NASH Drug Pipeline Sales Market Share Forecast by Country (2027-2032) Table 237. Latin America NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 238. Latin America NASH Drug Pipeline Market Size by Country (2021-2026) & (US$ Million) Table 239. Latin America NASH Drug Pipeline Market Share by Country (2021-2026) Table 240. Latin America NASH Drug Pipeline Market Size Forecast by Country (2027-2032) & (US$ Million) Table 241. Latin America NASH Drug Pipeline Market Share Forecast by Country (2027-2032) Table 242. Middle East and Africa NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 243. Middle East and Africa NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 244. Middle East and Africa NASH Drug Pipeline Sales Market Share by Country (2021-2026) Table 245. Middle East and Africa NASH Drug Pipeline Sales Forecast by Country (2027-2032) & (K Units) Table 246. Middle East and Africa NASH Drug Pipeline Sales Market Share Forecast by Country (2027-2032) Table 247. Middle East and Africa NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 248. Middle East and Africa NASH Drug Pipeline Market Size by Country (2021-2026) & (US$ Million) Table 249. Middle East and Africa NASH Drug Pipeline Market Share by Country (2021-2026) Table 250. Middle East and Africa NASH Drug Pipeline Market Size Forecast by Country (2027-2032) & (US$ Million) Table 251. Middle East and Africa NASH Drug Pipeline Market Share Forecast by Country (2027-2032) Table 252. Key Raw Materials Table 253. Raw Materials Key Suppliers Table 254. NASH Drug Pipeline Distributors List Table 255. NASH Drug Pipeline Customers List Table 256. Research Programs/Design for This Report Table 257. Authors List of This Report Table 258. Secondary Sources Table 259. Primary Sources List of Figures Figure 1. NASH Drug Pipeline Image Figure 2. Global NASH Drug Pipeline Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NASH Drug Pipeline Market Size (2021-2032) & (US$ Million) Figure 4. Global NASH Drug Pipeline Sales (2021-2032) & (K Units) Figure 5. Type One Image Figure 6. Type One Image Figure 7. Global NASH Drug Pipeline Market Size Overview by Type (2021-2032) & (US$ Million) Figure 8. Global NASH Drug Pipeline Market Share by Type 2025 VS 2032 Figure 9. North America NASH Drug Pipeline Sales Market Share in Volume by Type in 2025 Figure 10. North America NASH Drug Pipeline Sales Market Share in Value by Type in 2025 Figure 11. Europe NASH Drug Pipeline Sales Market Share in Volume by Type in 2025 Figure 12. Europe NASH Drug Pipeline Sales Market Share in Value by Type in 2025 Figure 13. Asia-Pacific NASH Drug Pipeline Sales Market Share in Volume by Type in 2025 Figure 14. Asia-Pacific NASH Drug Pipeline Sales Market Share in Value by Type in 2025 Figure 15. Latin America NASH Drug Pipeline Sales Market Share in Volume by Type in 2025 Figure 16. Latin America NASH Drug Pipeline Sales Market Share in Value by Type in 2025 Figure 17. Middle East and Africa NASH Drug Pipeline Sales Market Share in Volume by Type in 2025 Figure 18. Middle East and Africa NASH Drug Pipeline Sales Market Share in Value by Type in 2025 Figure 19. Global Top 5 and 10 NASH Drug Pipeline Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Clinical Image Figure 22. Global Clinical Sales YoY Growth (2021-2032) & (K Units) Figure 23. Academic Research Image Figure 24. Global Academic Research Sales YoY Growth (2021-2032) & (K Units) Figure 25. Global NASH Drug Pipeline Market Size Overview by Application (2021-2032) & (US$ Million) Figure 26. Global NASH Drug Pipeline Market Share by Application 2025 VS 2032 Figure 27. North America NASH Drug Pipeline Sales Market Share in Volume by Application in 2025 Figure 28. North America NASH Drug Pipeline Sales Market Share in Value by Application in 2025 Figure 29. Europe NASH Drug Pipeline Sales Market Share in Volume by Application in 2025 Figure 30. Europe NASH Drug Pipeline Sales Market Share in Value by Application in 2025 Figure 31. Asia-Pacific NASH Drug Pipeline Sales Market Share in Volume by Application in 2025 Figure 32. Asia-Pacific NASH Drug Pipeline Sales Market Share in Value by Application in 2025 Figure 33. Latin America NASH Drug Pipeline Sales Market Share in Volume by Application in 2025 Figure 34. Latin America NASH Drug Pipeline Sales Market Share in Value by Application in 2025 Figure 35. Middle East and Africa NASH Drug Pipeline Sales Market Share in Volume by Application in 2025 Figure 36. Middle East and Africa NASH Drug Pipeline Sales Market Share in Value by Application in 2025 Figure 37. North America NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 38. North America NASH Drug Pipeline Sales Share by Country: 2021 VS 2025 VS 2032 Figure 39. North America NASH Drug Pipeline Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. North America NASH Drug Pipeline Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. Europe NASH Drug Pipeline Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe NASH Drug Pipeline Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe NASH Drug Pipeline Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Asia-Pacific NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Asia-Pacific NASH Drug Pipeline Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific NASH Drug Pipeline Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Asia-Pacific NASH Drug Pipeline Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Latin America NASH Drug Pipeline Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America NASH Drug Pipeline Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America NASH Drug Pipeline Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Middle East and Africa NASH Drug Pipeline Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Middle East and Africa NASH Drug Pipeline Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa NASH Drug Pipeline Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Middle East and Africa NASH Drug Pipeline Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. NASH Drug Pipeline Value Chain Figure 58. Key Raw Materials Price Figure 59. Manufacturing Cost Structure Figure 60. NASH Drug Pipeline Production Mode & Process Figure 61. Direct Comparison with Distribution Share Figure 62. Distributors Profiles Figure 63. Years Considered Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Applications
  • Clinical
  • Academic Research
Companies covered
  • 89bio Inc
  • ABIONYX Pharma SA
  • Abivax SA
  • Abliva AB
  • Acquist Therapeutics
  • AdAlta Ltd
  • Afimmune Biopharma Ltd
  • Allergan
  • ChemomAb Ltd
  • Dicerna Pharmaceuticals Inc
  • DURECT Corp
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • EncuraGen Inc
  • Engitix Ltd
  • Galectin
  • Genfit
  • Gilead
  • Heprotech Inc
  • Hinova Pharmaceuticals Inc
  • HK inno.N Corp
  • HotSpot Therapeutics Inc
  • Immuron
  • Intercept
  • Madrigal
  • Zhejiang Doer Biologics Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NASH Drug Pipeline Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global NASH Drug Pipeline Sales Estimates and Forecasts (2021-2032)
  5. 1.3 NASH Drug Pipeline Market by Type
  6. 1.3.1 By Molecule Types
  7. 1.3.2 By Route of Administration:
  8. 1.3.3 By Mechanism of Action
  9. 1.4 Global NASH Drug Pipeline Market Size by Type
  10. 1.4.1 Global NASH Drug Pipeline Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global NASH Drug Pipeline Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global NASH Drug Pipeline Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America NASH Drug Pipeline Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe NASH Drug Pipeline Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific NASH Drug Pipeline Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America NASH Drug Pipeline Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa NASH Drug Pipeline Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 NASH Drug Pipeline Industry Trends
  2. 2.2 NASH Drug Pipeline Industry Drivers
  3. 2.3 NASH Drug Pipeline Industry Opportunities and Challenges
  4. 2.4 NASH Drug Pipeline Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by NASH Drug Pipeline Revenue (2021-2026)
  2. 3.2 Global Top Players by NASH Drug Pipeline Sales (2021-2026)
  3. 3.3 Global Top Players by NASH Drug Pipeline Price (2021-2026)
  4. 3.4 Global NASH Drug Pipeline Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global NASH Drug Pipeline Major Company Production Sites & Headquarters
  6. 3.6 Global NASH Drug Pipeline Company, Product Type & Application
  7. 3.7 Global NASH Drug Pipeline Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global NASH Drug Pipeline Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 NASH Drug Pipeline Players Market Share by Revenue in 2025
  11. 3.8.3 2025 NASH Drug Pipeline Tier 1, Tier 2, and Tier 3
4 NASH Drug Pipeline Regional Status and Outlook
  1. 4.1 Global NASH Drug Pipeline Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global NASH Drug Pipeline Historic Market Size by Region
  3. 4.2.1 Global NASH Drug Pipeline Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global NASH Drug Pipeline Sales in Value by Region (2021-2026)
  5. 4.2.3 Global NASH Drug Pipeline Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global NASH Drug Pipeline Forecasted Market Size by Region
  7. 4.3.1 Global NASH Drug Pipeline Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global NASH Drug Pipeline Sales in Value by Region (2027-2032)
  9. 4.3.3 Global NASH Drug Pipeline Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 NASH Drug Pipeline by Application
  1. 5.1 NASH Drug Pipeline Market by Application
  2. 5.1.1 Clinical
  3. 5.1.2 Academic Research
  4. 5.2 Global NASH Drug Pipeline Market Size by Application
  5. 5.2.1 Global NASH Drug Pipeline Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global NASH Drug Pipeline Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global NASH Drug Pipeline Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America NASH Drug Pipeline Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe NASH Drug Pipeline Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific NASH Drug Pipeline Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America NASH Drug Pipeline Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa NASH Drug Pipeline Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 89bio Inc
  2. 6.1.1 89bio Inc Company Information
  3. 6.1.2 89bio Inc Business Overview
  4. 6.1.3 89bio Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 89bio Inc NASH Drug Pipeline Product Portfolio
  6. 6.1.5 89bio Inc Recent Developments
  7. 6.2 ABIONYX Pharma SA
  8. 6.2.1 ABIONYX Pharma SA Company Information
  9. 6.2.2 ABIONYX Pharma SA Business Overview
  10. 6.2.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio
  12. 6.2.5 ABIONYX Pharma SA Recent Developments
  13. 6.3 Abivax SA
  14. 6.3.1 Abivax SA Company Information
  15. 6.3.2 Abivax SA Business Overview
  16. 6.3.3 Abivax SA NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Abivax SA NASH Drug Pipeline Product Portfolio
  18. 6.3.5 Abivax SA Recent Developments
  19. 6.4 Abliva AB
  20. 6.4.1 Abliva AB Company Information
  21. 6.4.2 Abliva AB Business Overview
  22. 6.4.3 Abliva AB NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Abliva AB NASH Drug Pipeline Product Portfolio
  24. 6.4.5 Abliva AB Recent Developments
  25. 6.5 Acquist Therapeutics
  26. 6.5.1 Acquist Therapeutics Company Information
  27. 6.5.2 Acquist Therapeutics Business Overview
  28. 6.5.3 Acquist Therapeutics NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Acquist Therapeutics NASH Drug Pipeline Product Portfolio
  30. 6.5.5 Acquist Therapeutics Recent Developments
  31. 6.6 AdAlta Ltd
  32. 6.6.1 AdAlta Ltd Company Information
  33. 6.6.2 AdAlta Ltd Business Overview
  34. 6.6.3 AdAlta Ltd NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 AdAlta Ltd NASH Drug Pipeline Product Portfolio
  36. 6.6.5 AdAlta Ltd Recent Developments
  37. 6.7 Afimmune Biopharma Ltd
  38. 6.7.1 Afimmune Biopharma Ltd Company Information
  39. 6.7.2 Afimmune Biopharma Ltd Business Overview
  40. 6.7.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio
  42. 6.7.5 Afimmune Biopharma Ltd Recent Developments
  43. 6.8 Allergan
  44. 6.8.1 Allergan Company Information
  45. 6.8.2 Allergan Business Overview
  46. 6.8.3 Allergan NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Allergan NASH Drug Pipeline Product Portfolio
  48. 6.8.5 Allergan Recent Developments
  49. 6.9 ChemomAb Ltd
  50. 6.9.1 ChemomAb Ltd Company Information
  51. 6.9.2 ChemomAb Ltd Business Overview
  52. 6.9.3 ChemomAb Ltd NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 ChemomAb Ltd NASH Drug Pipeline Product Portfolio
  54. 6.9.5 ChemomAb Ltd Recent Developments
  55. 6.10 Dicerna Pharmaceuticals Inc
  56. 6.10.1 Dicerna Pharmaceuticals Inc Company Information
  57. 6.10.2 Dicerna Pharmaceuticals Inc Business Overview
  58. 6.10.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  60. 6.10.5 Dicerna Pharmaceuticals Inc Recent Developments
  61. 6.11 DURECT Corp
  62. 6.11.1 DURECT Corp Company Information
  63. 6.11.2 DURECT Corp Business Overview
  64. 6.11.3 DURECT Corp NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 DURECT Corp NASH Drug Pipeline Product Portfolio
  66. 6.11.5 DURECT Corp Recent Developments
  67. 6.12 Eli Lilly and Co
  68. 6.12.1 Eli Lilly and Co Company Information
  69. 6.12.2 Eli Lilly and Co Business Overview
  70. 6.12.3 Eli Lilly and Co NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Eli Lilly and Co NASH Drug Pipeline Product Portfolio
  72. 6.12.5 Eli Lilly and Co Recent Developments
  73. 6.13 Enanta Pharmaceuticals Inc
  74. 6.13.1 Enanta Pharmaceuticals Inc Company Information
  75. 6.13.2 Enanta Pharmaceuticals Inc Business Overview
  76. 6.13.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  78. 6.13.5 Enanta Pharmaceuticals Inc Recent Developments
  79. 6.14 EncuraGen Inc
  80. 6.14.1 EncuraGen Inc Company Information
  81. 6.14.2 EncuraGen Inc Business Overview
  82. 6.14.3 EncuraGen Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 EncuraGen Inc NASH Drug Pipeline Product Portfolio
  84. 6.14.5 EncuraGen Inc Recent Developments
  85. 6.15 Engitix Ltd
  86. 6.15.1 Engitix Ltd Company Information
  87. 6.15.2 Engitix Ltd Business Overview
  88. 6.15.3 Engitix Ltd NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Engitix Ltd NASH Drug Pipeline Product Portfolio
  90. 6.15.5 Engitix Ltd Recent Developments
  91. 6.16 Galectin
  92. 6.16.1 Galectin Company Information
  93. 6.16.2 Galectin Business Overview
  94. 6.16.3 Galectin NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Galectin NASH Drug Pipeline Product Portfolio
  96. 6.16.5 Galectin Recent Developments
  97. 6.17 Genfit
  98. 6.17.1 Genfit Company Information
  99. 6.17.2 Genfit Business Overview
  100. 6.17.3 Genfit NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Genfit NASH Drug Pipeline Product Portfolio
  102. 6.17.5 Genfit Recent Developments
  103. 6.18 Gilead
  104. 6.18.1 Gilead Company Information
  105. 6.18.2 Gilead Business Overview
  106. 6.18.3 Gilead NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Gilead NASH Drug Pipeline Product Portfolio
  108. 6.18.5 Gilead Recent Developments
  109. 6.19 Heprotech Inc
  110. 6.19.1 Heprotech Inc Company Information
  111. 6.19.2 Heprotech Inc Business Overview
  112. 6.19.3 Heprotech Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Heprotech Inc NASH Drug Pipeline Product Portfolio
  114. 6.19.5 Heprotech Inc Recent Developments
  115. 6.20 Hinova Pharmaceuticals Inc
  116. 6.20.1 Hinova Pharmaceuticals Inc Company Information
  117. 6.20.2 Hinova Pharmaceuticals Inc Business Overview
  118. 6.20.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  120. 6.20.5 Hinova Pharmaceuticals Inc Recent Developments
  121. 6.21 HK inno.N Corp
  122. 6.21.1 HK inno.N Corp Company Information
  123. 6.21.2 HK inno.N Corp Business Overview
  124. 6.21.3 HK inno.N Corp NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 HK inno.N Corp NASH Drug Pipeline Product Portfolio
  126. 6.21.5 HK inno.N Corp Recent Developments
  127. 6.22 HotSpot Therapeutics Inc
  128. 6.22.1 HotSpot Therapeutics Inc Company Information
  129. 6.22.2 HotSpot Therapeutics Inc Business Overview
  130. 6.22.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio
  132. 6.22.5 HotSpot Therapeutics Inc Recent Developments
  133. 6.23 Immuron
  134. 6.23.1 Immuron Company Information
  135. 6.23.2 Immuron Business Overview
  136. 6.23.3 Immuron NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Immuron NASH Drug Pipeline Product Portfolio
  138. 6.23.5 Immuron Recent Developments
  139. 6.24 Intercept
  140. 6.24.1 Intercept Company Information
  141. 6.24.2 Intercept Business Overview
  142. 6.24.3 Intercept NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Intercept NASH Drug Pipeline Product Portfolio
  144. 6.24.5 Intercept Recent Developments
  145. 6.25 Madrigal
  146. 6.25.1 Madrigal Company Information
  147. 6.25.2 Madrigal Business Overview
  148. 6.25.3 Madrigal NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Madrigal NASH Drug Pipeline Product Portfolio
  150. 6.25.5 Madrigal Recent Developments
  151. 6.26 Zhejiang Doer Biologics Corp
  152. 6.26.1 Zhejiang Doer Biologics Corp Company Information
  153. 6.26.2 Zhejiang Doer Biologics Corp Business Overview
  154. 6.26.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio
  156. 6.26.5 Zhejiang Doer Biologics Corp Recent Developments
7 North America by Country
  1. 7.1 North America NASH Drug Pipeline Sales by Country
  2. 7.1.1 North America NASH Drug Pipeline Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America NASH Drug Pipeline Sales by Country (2021-2026)
  4. 7.1.3 North America NASH Drug Pipeline Sales Forecast by Country (2027-2032)
  5. 7.2 North America NASH Drug Pipeline Market Size by Country
  6. 7.2.1 North America NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America NASH Drug Pipeline Market Size by Country (2021-2026)
  8. 7.2.3 North America NASH Drug Pipeline Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe NASH Drug Pipeline Sales by Country
  2. 8.1.1 Europe NASH Drug Pipeline Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe NASH Drug Pipeline Sales by Country (2021-2026)
  4. 8.1.3 Europe NASH Drug Pipeline Sales Forecast by Country (2027-2032)
  5. 8.2 Europe NASH Drug Pipeline Market Size by Country
  6. 8.2.1 Europe NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe NASH Drug Pipeline Market Size by Country (2021-2026)
  8. 8.2.3 Europe NASH Drug Pipeline Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific NASH Drug Pipeline Sales by Country
  2. 9.1.1 Asia-Pacific NASH Drug Pipeline Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific NASH Drug Pipeline Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific NASH Drug Pipeline Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific NASH Drug Pipeline Market Size by Country
  6. 9.2.1 Asia-Pacific NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific NASH Drug Pipeline Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific NASH Drug Pipeline Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America NASH Drug Pipeline Sales by Country
  2. 10.1.1 South America NASH Drug Pipeline Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America NASH Drug Pipeline Sales by Country (2021-2026)
  4. 10.1.3 South America NASH Drug Pipeline Sales Forecast by Country (2027-2032)
  5. 10.2 South America NASH Drug Pipeline Market Size by Country
  6. 10.2.1 South America NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America NASH Drug Pipeline Market Size by Country (2021-2026)
  8. 10.2.3 South America NASH Drug Pipeline Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa NASH Drug Pipeline Sales by Country
  2. 11.1.1 Middle East and Africa NASH Drug Pipeline Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa NASH Drug Pipeline Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa NASH Drug Pipeline Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa NASH Drug Pipeline Market Size by Country
  6. 11.2.1 Middle East and Africa NASH Drug Pipeline Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa NASH Drug Pipeline Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa NASH Drug Pipeline Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 NASH Drug Pipeline Value Chain Analysis
  2. 12.1.1 NASH Drug Pipeline Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 NASH Drug Pipeline Production Mode & Process
  7. 12.2 NASH Drug Pipeline Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 NASH Drug Pipeline Distributors
  10. 12.2.3 NASH Drug Pipeline Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst